SCHEMBL23979460

SCHEMBL23979460

CC(C)(C)OC(=O)NCc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.47
GAA P10253 2/20 0.45
ACLY P53396 1/20 0.43
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.43
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.43
ALOX12 P18054 1/20 0.43
KDM4A O75164 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
KCNA5 P22460 1/20 0.41
HTT P42858 2/20 0.41
CYP2C9 P11712 1/20 0.41
PTGER1 P34995 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23979459 0.88 ABL1 (0.48) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL6921464 0.87 IDO1 (0.50) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL16790458 0.86 EPHX2 (0.48) ACLYMAPTKDM4AKCNA5MYC
SCHEMBL27988801 0.85 IDO1 (0.53) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL4296419 0.84 IDO1 (0.46) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL28215080 0.84 KDM4A (0.42) KDM4AKCNA5
SCHEMBL23997640 0.83 IDO1 (0.52) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL3734185 0.83 ANO1 (0.51) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL21987969 0.82 IDO1 (0.48) IDO1GAAALDH1A1KDM4EHPGD
SCHEMBL4757294 0.82 GAA (0.49) IDO1GAAALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667236-B 1, 5-Dihydro-2, 4-benzodiazepine-3-one derivative and application thereof 江苏恩华药业股份有限公司 2024-04-26 CN disclosed
US-20230132621-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) 2023-05-04 US disclosed
CN-115667236-A 1,5-dihydro-2,4-benzodiazepine-3-one derivative and use thereof 江苏恩华药业股份有限公司 2023-01-31 CN disclosed
WO-2021218863-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF 江苏恩华药业股份有限公司 (CN) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132621-A1 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF HTR2C, HTR2A, HTR2B IDO1 1690/4885GAA 1765/4885ACLY 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.